[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:myxofibrosarcoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":47,"states":48},"Myxofibrosarcoma",6,[7,15,21,28,35,41],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07283731","Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced\u002FMetastatic Soft-tissue Sarcoma",[11],"Phase 2","RECRUITING","2026-08-26T02:17:43.321968Z","2026-05-05T02:43:27.740604Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT04332874","A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg",[11],"2026-08-26T02:16:50.548894Z","2026-05-05T02:43:27.645373Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":26,"content_modified":27},"NCT06239272","NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)",[25],"Phase 1\u002FPhase 2","2026-08-26T02:18:06.247899Z","2026-07-19T19:36:05.068230Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":33,"content_modified":34},"NCT05711615","Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma",[32],"Phase 1","2026-08-26T02:19:30.857183Z","2026-07-05T05:32:16.811405Z",{"nct_id":36,"title":37,"phases":38,"status":12,"updated_at":39,"content_modified":40},"NCT06789172","A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors",[32],"2026-08-26T02:16:18.872924Z","2026-07-05T05:32:16.698119Z",{"nct_id":42,"title":43,"phases":44,"status":12,"updated_at":45,"content_modified":46},"NCT06113809","Palbociclib and Pembrolizumab in Sarcoma",[32],"2026-08-26T02:17:39.857430Z","2026-05-05T02:35:31.898243Z",[],[49],{"state":50,"count":51,"slug":52},"Texas",3,"texas"]